Comekibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Comekibart Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Comekibart can convert its Monoclonal antibody profile and IL-4Rα biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Comekibart (query alias: Comekibart) |
|---|---|
| Modality / target | Monoclonal antibody; IL-4Rα; IL-4Rα inhibitors |
| Highest global status | NDA/BLA |
| Originator | Hunan Mabgeek Biotechnology Co., Ltd. |
| Active developers | Hunan Mabgeek Biotechnology Co., Ltd., Shang Hai Mai Ji Yi Yao You Xian Gong Si, Chime Biologics Ltd. |
The MCP disease footprint includes Rhinitis, Allergic, Seasonal, Moderate Atopic Dermatitis, Severe Atopic Dermatitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07479615 | Phase 3 | Not yet recruiting | 498 | To evaluate the efficacy of MG K10 monotherapy compared to placebo in adults and adolescents with moderate to severe atopic dermatitis (AD). |
| NCT07546487 | Phase 3 | Not yet recruiting | 226 | Outcome Measure |
| NCT07540442 | Phase 3 | Not yet recruiting | 180 | Proportion of participants achieving EASI-75 ( ≥75% reduction from baseline ) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Phase Ib/ <scp>II</scp> Study of Preliminary Efficacy, Safety and Pharmacodynamics of <scp>MG</scp> ‐ <scp>K10</scp> , a Humanised Monoclonal Antibody Targeting <scp>IL</scp> ‐ <scp>4Rα</scp> , in Adult Chinese Patients With Asthma
Phase 1/2; n=187; evaluation: Positive. Reported fields: AE = 85.0 % ; AE = 79.7 % ; AE = 79.4 %
【天瑞动态】恭贺已投企业——麦济生物全球首个长效1L-4Rα单抗MG-K10中重度特应性皮炎适应症上市申请获受理
临床3期; n=not disclosed; evaluation: 积极. Reported fields: IGA(0或1分,较基线改善≥2分，第52周) = 76.6 % 达到
快讯 | 麦济生物获得慢性自发性荨麻疹（CSU）III期临床试验批准通知书
临床3期; n=not disclosed; evaluation: 积极. Reported fields: 主要终点 = 达到 达到
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Comekibart addresses Rhinitis, Allergic, Seasonal, Moderate Atopic Dermatitis, Severe Atopic Dermatitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-01-24 | 新产品布局丨康哲药业获得1类新药长效抗IL-4Rα单抗MG-K10 | Phase 3 | Financial terms not disclosed |
| 2022-03-09 | 麦济生物与鼎康生物签署战略合作，助力呼吸/免疫领域创新生物药驶入快车道 | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
